Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR)
- 525 Downloads
Bioavailability of clopidogrel in the form of crushed tablets administered via nasogastric tube (NGT) has not been established in patients after cardiopulmonary resuscitation. Therefore, we performed a study comparing pharmacokinetic and pharmacodynamic response to high loading dose of clopidogrel in critically ill patients after cardiopulmonary resuscitation (CPR) with patients scheduled for elective coronary angiography with stent implantation.
In the NGT group (nine patients, after cardiopulmonary resuscitation, mechanically ventilated, therapeutic hypothermia), clopidogrel was administered in the form of crushed tablets via NGT. Ten patients undergoing elective coronary artery stenting took clopidogrel per os (po) in the form of intact tablets. Pharmacokinetics of clopidogrel was measured with high-performance liquid chromatography (HPLC) before and at 0.5, 1, 6, 12, 24 h after administration of a loading dose of 600 mg. In five patients in each group, antiplatelet effect was measured with thrombelastography (TEG; Platelet Mapping) before and 24 h after administration.
The carboxylic acid metabolite of clopidogrel was detected in all patients in the po group. In eight patients, the maximum concentration was measured in the range of 0.5–1 h after the initial dose. In four patients in the of NGT group, the carboxylic acid metabolite of clopidogrel was undetectable and in the remaining patients was significantly delayed (peak values at 12 h). All patients in the po group reached clinically relevant (>50 %) inhibition of thrombocyte adenosine diphosphate (ADP) receptor after 24 h compared with only two in the NGT group (p = 0.012). There was a close correlation between peak of inactive clopidogrel metabolite plasmatic concentration and inhibition of the ADP receptor (r = 0.79; p < 0.001).
The bioavailability of clopidogrel in critically ill patients after cardiopulmonary resuscitation is significantly impaired compared with stable patients. Therefore, other drugs, preferentially administered intravenously, should be considered.
KeywordsClopidogrel Pharmacokinetics Thrombelastography HPLC
- 5.Antman EM, Hand M, Amstrong PW, Bate ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC (2008) 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practise guidelines. Circulation 117(2):296–329PubMedCrossRefGoogle Scholar
- 6.Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S (2008) Design and rationale of CURRENT-OASIS: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 156(6):1080–1088PubMedCrossRefGoogle Scholar
- 7.Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W (2005) Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26(8):804–847PubMedCrossRefGoogle Scholar
- 8.Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY Study. JAMA 294(10):1224–1232PubMedCrossRefGoogle Scholar
- 10.PLAVIXTM, RxMed: Pharmaceutical Information, Sanofi/Bristol- Mayers Squibb www.RXlist.com
- 13.Beckwith MC, Feddema SS, Barton RG, Graves C (2004) A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods. Hosp Pharm 39(3):225–237Google Scholar
- 19.Ernesto O, Martin H, Ronald D (2007) Clopidogrel resistance. Heart Lung Circ 16(3):17–28Google Scholar
- 21.Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey AA, Gibson CM, Giugliano RP, Mascelli MA, Scherer J, Barnathan ES, Braunwald E, Kleiman NS (2000) High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction). Circulation 101(23):2690–2695PubMedCrossRefGoogle Scholar
- 24.Nirogi RVS (2006) Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Mass Spectrom 20(11):1695–1700Google Scholar
- 25.Harlfinger S (2004) Pharmacokinetics of clopidogrel and its active matabolite in human plasma. Annual Scientific Session of the American College of Cardiology. New Orleans, LA. March 7–10Google Scholar
- 29.Bochsen L, Wiinberg B, Kjelgaard-Hansen M, Steinbruchel DA, Johanson PI (2007) Evaluation of TEG platelet mapping assay in blood donors. Thromb J 5(3):509–518Google Scholar
- 38.von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112(19):2946–2950Google Scholar
- 48.Cundrle I Jr, Sramek V, Zvonicek V (2010) Influence of temperature adjustment on thrombelasthography results. Intensive Care Med 36(2):152Google Scholar
- 49.Ruzicka J, Stengl M, Bolek L, Benes J, Matejovic M, Krouzecky A (2012) Hypothermic anticoagulation: testing individual responses to graded severe hypothermia with thromboelastography. Blood Coagul Fibrinolysis. Mar 3. [Epub ahead of print]Google Scholar
- 54.Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L, French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360(4):363–375PubMedCrossRefGoogle Scholar
- 57.Rao SV, Melloni C, Myles-Dimauro S, Broderick S, Kosinski AS, Kleiman NS, Dzavík V, Tanguay JF, Chandna H, Gammon R, Rivera E, Alexander JH, Fier I, Roach J, Becker RC, EMINENCE Investigators (2010) Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. Circulation 121(15):1713–1721PubMedCrossRefGoogle Scholar
- 59.Christian W, Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 1–56Google Scholar